The Korean Journal of Internal Medicine
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Diffuse large B-cell lymphoma: Early patient management | OTT
![PDF] Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/51a4a761ac9c47aeab4203b78043f3c50a5bbe83/2-Table1-1.png "PDF] Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. | Semantic Scholar")
PDF] Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. | Semantic Scholar
Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy | Annals of Hematology
A: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System - The ASCO Post
Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma - Hematology Advisor
Patient Information: Diffuse Large B Cell Lymphoma
New agents and regimens for diffuse large B cell lymphoma | Journal of Hematology & Oncology | Full Text
Evolution of therapy for limited stage diffuse large B-cell lymphoma | Blood Cancer Journal
Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? | Haematologica
Overall survival of patients with diffuse large B-cell lymphoma... | Download Scientific Diagram
Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular ...
About RITUXAN® (rituximab) | Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma - an overview | ScienceDirect Topics
Progression-free survival in diffuse large B cell lymphoma patients in... | Download Scientific Diagram
Survival analysis in patients with diffuse large B-cell lymphoma... | Download Scientific Diagram
Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen | Journal of Nuclear Medicine
![PDF] Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/910db6912e5f808721d987fcdb285a61b2b6afb3/2-Table1-1.png "PDF] Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. | Semantic Scholar")
PDF] Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. | Semantic Scholar
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study | Haematologica
RELB AS A NOVEL PROGNOSTIC BIOMARKER FOR DIFFUSE LARGE B-CELL LYMPHOMA ( DLBCL) | ERGANEO
Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Frontiers | Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study
A modified prognostic model in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy
Diffuse Large B-Cell Lymphoma (DLBCL): Symptoms, Treatment and Prognosis – Nova Science Publishers
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
